All generics articles
-
BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
BusinessEurope gears up for streamlined patent system
Delayed Unified Patent Court set to begin operating in April
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
BusinessCalifornia advances plans to make its own insulin
Governor commits $100 million to develop low-cost insulin and build manufacturing facility to strengthen drug’s supply chain
-
BusinessPfizer’s Upjohn to merge with Mylan
Deal combines Pfizer’s off-patent drug portfolio with Mylan’s generics
-
BusinessUS finalises guidance on biosimilars
Regulator clarifies requirements for allowing substitution between products
-
BusinessNon-profit generic drug company created
Intermountain Healthcare is leading an effort in the US to prevent drug shortages and end their skyrocketing prices
-
BusinessTeva to cut 14,000 jobs
Saddled with debt in an increasingly competitive generic drug industry, the Israel-headquartered giant begins a difficult transformation
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessUS state passes law blocking generic drug price-gouging
Despite industry opposition, Maryland will be able to fine companies for ‘excessive and unjustified’ price increases
-
BusinessAllergan sidesteps patent review with tribal deal
Native Americans agree to use sovereign immunity to protect intellectual property from double challenge
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessIndia’s Intas bags UK and Irish generics
Teva sheds former Actavis business to satisfy competition requirements of its Allergan generics takeover
-
Business
Teva sells off products in preparation for Allergan merger
Generics deals with Impax, Dr Reddy’s and Sagent aimed at satisfying competition authorities
-
BusinessIndia hit hard by US regulatory sanctions
Data integrity issues have led to punitive measures, but companies are taking measures to improve
-
BusinessMylan expands in dermatology
$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio